Highest-materiality recent filing
Arcturus Q1 net loss widens to $27M; appoints Dennis Mulroy as CFO
Net loss of $27.0M ($0.95/diluted share), compared to $14.1M loss ($0.52/share) in Q1 2025.
Arcturus FY2025 net loss narrows to $65.8M; revenue falls 46% to $82M; CF program advances
Q4 net loss $29.1M ($1.03/shr) vs $30.0M loss prior year; FY net loss $65.8M ($2.40/shr) vs $80.9M.
CFO Andy Sassine to depart Dec 31, 2025; Controller Joe Roberts named interim CFO
CFO Andy Sassine and Arcturus mutually agreed to end employment effective Dec 31, 2025; he also resigned from the Board.
Arcturus Therapeutics Reports Q3 2025 Net Loss of $13.5M, Progresses ARCT-032 and ARCT-810 Programs
Q3 2025 revenue was $17.2M, down $24.5M from prior year; net loss $13.5M ($0.49 per share) vs $6.9M loss in Q3 2024.
ARCT-032 Phase 2 interim: generally safe/tolerated; 4 of 6 Class I CF patients showed mucus plug/volume reduction after 28 days (10 mg).
Meiji Seika Pharma receives Japan approval for two-dose vial of KOSTAIVE® COVID-19 vaccine
Approval granted August 28, 2025 for new two-dose vial presentation of KOSTAIVE® (ARCT-2301) in Japan.
Arcturus ARCT-810 Phase 2 interim: glutamine normalized, ureagenesis improved (p=0.026)
Combined Phase 2 data show glutamine significantly reduced (p=0.0055); levels normalized after 3 doses in US study.
Arcturus Q1 net loss narrows to $14.1M; cash runway extends into 2028
Net loss $14.1M ($0.52/diluted share) vs $26.8M ($1.00) a year ago; revenue $29.4M down 23% YoY.
Arcturus Q4 net loss widens to $30M; KOSTAIVE EC approved, Phase 2 data due Q2 2025
Q4 2024 net loss $30.0M ($1.11/share) vs $11.7M ($0.44) in Q4 2023; revenue down $8.1M to $22.8M.
Arcturus Q3 net loss narrows to $6.9M; $25M milestone from KOSTAIVE first sale in Japan
Q3 revenue $41.7M vs $45.2M YoY, down on lower CSL milestones; net loss $6.9M ($0.26/sh) vs $16.2M ($0.61/sh).
Arcturus Q2 revenue $49.9M, net loss $17.2M; pipeline advances, Kostaive launch on track
Revenue $49.9M, up $39.4M YoY from $10.5M, driven by CSL collaboration revenue.
Q1 2024 revenue $38.0M (down 53% YoY); net loss $26.8M ($1.00/share) vs net income $50.8M ($1.87) in Q1 2023.
Arcturus partner Meiji reports Phase III success for bivalent COVID-19 booster in Japan
Bivalent ARCT-2301 (Kostaive) met primary endpoint of non-inferiority vs COMIRNATY bivalent in GMT ratio and SRR difference.
Arcturus Therapeutics amends FY2023 results: revenue down $3.2M, net loss wider
Collaboration revenue for FY2023 decreased from $160.9M to $157.7M; Q4 2023 from $28.2M to $25.0M.
Arcturus FY2023 revenue $169.9M, net loss $26.6M; cash runway extended to Q1 2027
FY2023 revenue $169.9M (down from $206.0M); net loss $26.6M ($1.00 diluted EPS) vs prior year net income $9.3M ($0.35 EPS).
Effective May 1, 2026, Dennis Mulroy, 71, was appointed Chief Financial Officer of the Company.
On June 19, 2024, Dr. Moncef Slaoui, Ph.D., agreed to serve as a member of the Board of Directors
Joseph Roberts, formerly the Company’s Assistant Controller, has been promoted to Controller of the Company.
Keith C. Kummerfeld, Senior Vice President of Finance and Corporate Controller of Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”), informed the Company that he will resign from his position with the Company, effective March 15, 2024, to pursue another opportunity.
Max materiality 0.90 · Median 0.62 · Most common event earnings